December 19, 2018
December 19, 2018 – The U.S. FDA has approved a new indication for Keytruda® (pembrolizumab), manufactured by Merck. Under the new indication, Keytruda is now approved to treat of adult and pediatric patients who have recurrent locally advanced or metastatic Merkel cell carcinoma (MCC).